Table 1. Distribution of sex, tumor stage, metastasis score, tumor size, race, subtype, and lymph node stage (for CRC only) across BRCA1 mRNA-low versus -high groups in BC and CRC.
| BC | CRC | ||||
|---|---|---|---|---|---|
| BRCA1 low
(n = 85) |
BRCA1 high
(n = 148) |
BRCA1 low
(n = 38) |
BRCA1 high
(n = 51) |
||
| Sex | Female | 85/85 (100%) | 142/148 (96%) | 18/38 (47%) | 17/51 (33%) |
| Male | 0/85 (0%) | 6/148 (4%) | 20/38 (53%) | 33/51 (65%) | |
| N/A | 0/85 (0%) | 0/148 (0%) | 0/38 (0%) | 1/51 (2%) | |
| Tumor Stage | I | 17/85 (20%) | 15/148 (10%) | 4/38 (11%) | 5/51 (10%) |
| II | 47/85 (55%) | 98/148 (66%) | 10/38 (26%) | 19/51 (37%) | |
| III | 21/85 (25%) | 31/148 (21%) | 11/38 (29%) | 15/51 (29%) | |
| IV | 0/85 (0%) | 2/148 (1%) | 9/38 (24%) | 8/51 (16%) | |
| X | 0/85 (0%) | 1/148 (1%) | 0/38 (0%) | 0/51 (0%) | |
| N/A | 0/85 (0%) | 1/148 (1%) | 4/38 (11%) | 4/51 (8%) | |
| Metastasis Score | M0 | 68/85 (80%) | 132/148 (89%) | 19/38 (50%) | 31/51 (61%) |
| M1 | 0/85 (0%) | 4/148 (3%) | 8/38 (21%) | 9/51 (18%) | |
| MX | 17/85 (20%) | 12/148 (8%) | 9/38 (24%) | 10/51 (20%) | |
| N/A | 0/85 (0%) | 0/148 (0%) | 2/38 (5%) | 1/51 (2%) | |
| Tumor Size | T1 | 25/85 (29%) | 25/148 (17%) | 1/38 (3%) | 1/51 (2%) |
| T2 | 45/85 (53%) | 100/148 (68%) | 4/38 (11%) | 4/51 (8%) | |
| T3 | 14/85 (17%) | 18/148 (12%) | 24/38 (63%) | 40/51 (80%) | |
| T4 | 1/85 (1%) | 4/148 (3%) | 7/38 (18%) | 5/51 (10%) | |
| Tis | 0/85 (0%) | 0/148 (0%) | 1/38 (3%) | 0/38 (0%) | |
| N/A | 0/85 (0%) | 1/148 (1%) | 1/38 (3%) | 1/51 (2%) | |
| Race | White | 58/85 (68%) | 100/148 (68%) | 29/38 (76%) | 33/51 (65%) |
| Black or African American | 21/85 (25%) | 18/148 (12%) | 4/38 (11%) | 13/51 (26%) | |
| Asian | 3/85 (4%) | 11/148 (7%) | 3/38 (8%) | 2/51 (4%) | |
| N/A | 3/85 (4%) | 19/148 (13%) | 2/38 (5%) | 3/51 (6%) | |
| BC Subtype | Luminal A | 31/85 (36%) | 33/148 (22%) | ||
| Luminal B | 4/85 (5%) | 73/148 (49%) | |||
| Basal | 29/85 (34%) | 25/148 (17%) | |||
| Her2 | 5/85 (6%) | 7/148 (5%) | |||
| Normal | 6/85 (7%) | 0/148 (0%) | |||
| N/A | 10/85 (12%) | 10/148 (7%) | |||
| Lymph Node Stage | N0 | 16/38 (42%) | 29/51 (57%) | ||
| N1 | 11/38 (29%) | 12/51 (24%) | |||
| N2 | 10/38 (26%) | 9/51 (18%) | |||
| N/A | 1/38 (3%) | 1/51 (2%) | |||
| CRC Subtype | Colon Adenocarcinoma | 20/38 (53%) | 35/51 (69%) | ||
| Rectal Adenocarcinoma | 9/38 (24%) | 11/51 (22%) | |||
| Colorectal Adenocarcinoma | 0/38 (0%) | 1/51 (2%) | |||
| Mixed | 2/38 (5%) | 1/51 (2%) | |||
| Mucinous | 7/38 (18%) | 3/51 (6%) | |||